(NBSE) – Globe Newswire
-
NeuBase Therapeutics Announces Receipt of Notice from Nasdaq
-
Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance
-
NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder
-
NeuBase Therapeutics to Explore Strategic Alternatives
-
NeuBase Announces Closing of $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
-
NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors™ are Non-Immunogenic, Opening the Door to Redosing
-
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
-
NeuBase Announces 1-for-20 Reverse Stock Split
-
NeuBase to Participate in Jefferies Healthcare Conference
-
NeuBase Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors™
-
NeuBase Announces Formation of Gene Editing Advisory Board
-
NeuBase Reports Business Update and Financial Results for the First Quarter of 2023
-
NeuBase Therapeutics Selected to Present Two Oral Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting
-
NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2023
-
NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022
-
NeuBase Therapeutics Announces Gene Editing Research Agreement with Global Healthcare Company
-
NeuBase Therapeutics Announces Strategic Restructuring Focused on Advancing Its Platform in Gene Editing
-
NeuBase to Participate at Chardan’s 6th Annual Genetic Medicines Conference
-
NeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022
-
NeuBase Therapeutics Announces Promotion of Dr. William Mann to President and COO
-
NeuBase to Participate at the Jefferies Healthcare Conference
-
NeuBase Presents New Preclinical Data at ASGCT 2022 for Its DM1 Program Demonstrating Wide Tissue Distribution and Supporting a Differentiated Whole-Body Treatment Solution
-
NeuBase Therapeutics Reports Business Update and Financial Results for the Second Quarter of Fiscal Year 2022
-
NeuBase Therapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting
-
NeuBase Therapeutics Presents New Preclinical Data at MDA 2022 for Its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution, and Myotonia Reversal
-
NeuBase to Present at Oppenheimer’s 32nd Annual Healthcare Conference
-
NeuBase Therapeutics to Present New Preclinical Data for Myotonic Dystrophy Type 1 Program at the 2022 MDA Clinical & Scientific Conference
-
NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2022
-
NeuBase Therapeutics Appoints Todd P. Branning Chief Financial Officer
-
NeuBase Therapeutics Appoints Dr. Eric J. Ende to Board of Directors
-
NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2021
-
NeuBase to Present at the Jefferies London Healthcare Conference
-
VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States
-
NeuBase to Participate at the Chardan 5th Annual Genetic Medicines Conference
-
NeuBase to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
-
NeuBase Therapeutics Appoints Anthony Rossomando, Ph.D. as Chief Technology Officer
-
NeuBase Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investment Conference
-
NeuBase Therapeutics Reports Financial Results for the Third Quarter of Fiscal Year 2021 and Recent Operating Highlights
-
NeuBase Therapeutics Demonstrates Functional Rescue in Myotonic Dystrophy Type 1 Model and Allele-Selective Inhibition of KRAS Mutations to Inhibit Tumor Growth
-
NeuBase Therapeutics Announces Speakers for Virtual R&D Day Taking Place on June 8th
-
NeuBase Therapeutics Appoints Dr. Kia Motesharei Chief Business and Strategy Officer
-
NeuBase Therapeutics Appoints Dr. Sandra Rojas-Caro Chief Medical Officer
-
NeuBase Therapeutics to Participate in Upcoming Investor Conferences in May 2021
-
NeuBase Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2021
-
NeuBase Therapeutics Appoints Gerald J. McDougall to Board of Directors
-
NeuBase Therapeutics to Present at the B. Riley Securities’ Virtual Neuroscience Conference
-
NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
NeuBase Therapeutics Announces Pricing of $40 Million Public Offering of Common Stock
-
NeuBase Therapeutics Announces Proposed Public Offering of Common Stock
-
Coya Therapeutics™ Announces the Appointment of Hideki Garren, M.D., Ph.D., and Dov Goldstein, M.D., to Its Board of Directors
Back to NBSE Stock Lookup
